Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | RAD52 | P43351 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azepexole SCHEMBL10434847 | 0.98 | LMNA (1.00) | CYP3A4TSHRHSD17B10LMNABLM | |
| Azepexole SCHEMBL12481538 | 0.98 | LMNA (1.00) | CYP3A4TSHRHSD17B10LMNABLM | |
| SCHEMBL8030818 | 0.79 | CYP3A4 (0.65) | CYP3A4TSHRHSD17B10LMNABLM | |
| Hydrochloric Acid SCHEMBL10656025 | 0.78 | LMNA (0.66) | CYP3A4TSHRHSD17B10LMNABLM | |
| Hydrochloric Acid SCHEMBL11074525 | 0.70 | LMNA (0.57) | CYP3A4TSHRHSD17B10LMNABLM | |
| SCHEMBL25112168 | 0.69 | CYP3A4 (0.53) | CYP3A4TSHRHSD17B10LMNABLM | |
| Hydrochloric Acid SCHEMBL11066413 | 0.69 | LMNA (0.55) | CYP3A4TSHRHSD17B10LMNABLM | |
| SCHEMBL3761749 | 0.69 | CYP3A4 (0.53) | CYP3A4TSHRHSD17B10LMNABLM | |
| Hydrochloric Acid SCHEMBL11076075 | 0.69 | LMNA (0.55) | CYP3A4TSHRHSD17B10LMNABLM | |
| SCHEMBL6369625 | 0.69 | CYP3A4 (0.53) | CYP3A4TSHRHSD17B10LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472158-B2 | Methods of treating trigeminal nerve pain | VANDERBILT UNIVERSITY (US) | 2025-11-18 | — | — | US | claimed |
| WO-2024249843-A2 | GUANFACINE FOR FATIGUE DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| US-20230404979-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2023-12-21 | — | — | US | claimed |
| EP-4031000-A1 | SYSTEMS AND METHODS FOR DETECTION AND PREVENTION OF EMERGENCE OF AGITATION | Bioxcel Therapeutics, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220202373-A1 | SYSTEMS AND METHODS OF USING MACHINE LEARNING TO DETECT AND PREDICT EMERGENCE OF AGITATION BASED ON SYMPATHETIC NERVOUS SYSTEM ACTIVITIES | BIOXCEL THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | US | claimed |
| US-20220133656-A1 | METHODS OF TREATING TRIGEMINAL NERVE PAIN | VANDERBILT UNIVERSITY | 2022-05-05 | — | — | US | claimed |
| WO-2022093767-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-0399791-A1 | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | ALLERGAN, INC (US) | 1990-11-28 | — | — | EP | claimed |
| US-4970208-A | OXAZOLO-OR THIAZOLO 5,4-d!AZEPINES | BOEHRINGER INGELHEIM GMBH (DE) | 1990-11-13 | — | — | US | claimed |
| US-4826686-A | TRANSDERMAL PATCH FOR SUSTAINED RELEASE OF HYPOTENSIVE AGENT | BOEHRINGER INGELHEIM KG (DE) | 1989-05-02 | — | — | US | claimed |
| US-4783456-A | A-ADRENERGIC BLOCKING AGENTS | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 1988-11-08 | — | — | US | claimed |
| EP-0005732-B1 | Use of 2-amino-oxazolo- or 2-amino-thiazolo-[5,4-d]azepines and acid-addition salts thereof for the manufacture of a medicament for the treatment of Angina Pectoris | Dr. Karl Thomae GmbH (DE) | 1988-06-15 | — | — | EP | claimed |
| EP-0227988-A2 | Therapeutic system | BOEHRINGER INGELHEIM KG (DE) | 1987-07-08 | — | — | EP | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| US-4400378-A | THIAZOLO OR OXAZOLO COMPOUNDS | KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-08-23 | — | — | US | claimed |
| US-4259342-A | HYPOTENSIVE, SEDATIVE, ANTITUSSIVE, ANTIINFLAMMATORY | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-31 | — | — | US | claimed |
| EP-0005732-A1 | Use of 2-amino-oxazolo- or 2-amino-thiazolo-[5,4-d]azepines and acid-addition salts thereof for the manufacture of a medicament for the treatment of Angina Pectoris | Dr. Karl Thomae GmbH (DE) | 1979-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133656-A1 | METHODS OF TREATING TRIGEMINAL NERVE PAIN | NGF, ADRA2C, OPRL1 | CYP3A4 4442/4885TSHR 2302/4885HSD17B10 3350/4885 |
| US-12472158-B2 | Methods of treating trigeminal nerve pain | NGF, ADRA2C, OPRL1 | CYP3A4 4442/4885TSHR 2302/4885HSD17B10 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.